More severe psoriasis was associated with lower levels of quality of life.

Biologic therapy is a well-established strategy for managing moderate and severe psoriasis.

Subjects with moderate-to- severe psoriasis with a decision to receive secukinumab 300 mg were included.

PMID: 24018211 Biologic therapy is a well-established strategy for managing moderate and severe psoriasis.

Treating geriatric patients with moderate-to- severe psoriasis remains a challenge due to immunosenescence and comorbidities.

Efficacy and safety profiles of biologics have been established for moderate to severe psoriasis.

Overall, 1880 consecutive patients affected by mild-to- severe psoriasis were recruited.

Acitretin and bath PUVA may be safely combined for the treatment of severe psoriasis.

We prospectively studied left ventricular function in patients with severe psoriasis who initiated biologic therapy.

Besides skin inflammation, patients with severe psoriasis suffer from an increased risk of cardiovascular mortality.

Patients with moderate-to- severe psoriasis are often treated with systemic immunosuppressant agents that decrease immune system function.

Patients with moderate-to- severe psoriasis, those with psoriatic arthritis, or use of biologics contributes to higher healthcare costs.

Background: There is insufficient information on how best to treat moderate to severe psoriasis in difficult clinical circumstances.

In Europe, this group of drugs also has been approved for therapy of moderate to severe psoriasis recently.

Background: Ongoing evaluation of biological agents in patients with moderate-to- severe psoriasis is needed to support their long-term use.

Background: Etanercept and efalizumab recently became available and reimbursed for routine use in severe psoriasis in the Netherlands.